UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000024013
Receipt No. R000027457
Scientific Title A clinical study for evaluating the efficacy of "Zendamakin-no-chikara" containing Lactcoccus lactis subsp. Cremoris FC on fanction of intestinal bacterial flora regulation. -Randomised double-blind placebo-controlled trial
Date of disclosure of the study information 2016/09/16
Last modified on 2018/05/16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A clinical study for evaluating the efficacy of "Zendamakin-no-chikara" containing Lactcoccus lactis subsp. Cremoris FC on fanction of intestinal bacterial flora regulation. -Randomised double-blind placebo-controlled trial
Acronym A clinical study for evaluating the efficacy of "Zendamakin-no-chikara" containing Lactcoccus lactis subsp. Cremoris FC on fanction of intestinal bacterial flora regulation. -Randomised double-blind placebo-controlled trial
Scientific Title A clinical study for evaluating the efficacy of "Zendamakin-no-chikara" containing Lactcoccus lactis subsp. Cremoris FC on fanction of intestinal bacterial flora regulation. -Randomised double-blind placebo-controlled trial
Scientific Title:Acronym A clinical study for evaluating the efficacy of "Zendamakin-no-chikara" containing Lactcoccus lactis subsp. Cremoris FC on fanction of intestinal bacterial flora regulation. -Randomised double-blind placebo-controlled trial
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy of capsule containing Lactococcus lactis subsp. Cremoris FC on the function of intestinal regulation to subjects having tendency toward constipation.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Analysation of Enterobacterial flora (number of the total bacteria, Bifidobacterium genus, Lactobaccilus genus, Clostridium Perfringens) in feces by the real-time PCR method.
Time of assessment: before and two weeks after intake of active/placebo.
Key secondary outcomes Defecation frequency per day, Defecation frequency per week, Fecal amount.
Time of assessment: after two-week intake of active/placebo, defecation frequency, defecation frequency and fecal amount are assessed on a weekly basis.
Fecal shape, color and odor.Feeling after defecation.

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Capsule containing Lactococcus lactis subsp. Cremoris FC(100mg/serving) (2 weeks), washout(3 weeks), Placebo capsule(2 weeks)
Interventions/Control_2 Placebo capsule(2 weeks), washout(3 weeks), Capsule containing Lactococcus lactis subsp. Cremoris FC(100mg/serving) (2 weeks)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
30 years-old <=
Age-upper limit
60 years-old >
Gender Male and Female
Key inclusion criteria (1)(Healthy) subjects aged 30 to 59 years old
(2)Subjects who there were few ratios for the number of Bifidobacterium in the feces at the time of screening examination and unevenness was small
(4)Subjects giving written informed consent
Key exclusion criteria (1)Individuals taking antiflatulents and/or laxatives(including purgative drugs) in common use
(2)Individuals taking health foods in common use, including food for specified health use, which influence intestinal regulation at the point of screening examination
(3)Individuals taking antibiotics and/or drugs which influence laxatives(including purgative drugs) in common use at the point of screening examination
(4)Individuals daily consuming alcohol as equivalent amount of sake more than 360ml
(5)Individuals who are not able to stop consumption of foods containing lactic acid bacteria, bifidobacteria, natto bacteria, oligosaccharides, dietary fibers, high amount of sugar alcohol and/or other health foods including food for specified health use, which influence intestinal regulation during the study period
(6)Individuals presenting known food allergy
(7)Individuals who are suffered from a disease which needs treatment urgently or individuals with severe complications
(8)Individuals with a digestive organ disease or surgical history who has an influence on digestive absorption and defecation
(9)Individuals infected with a disease to urgently need treatment, or having serious complications
(10)Individuals who are pregnant or breast-feeding, or have the will of pregnancy during the study period
(11)Individuals who participate in other clinical studies or who are in willing to participate to these studies using foods, drugs and/or cosmetics
(12)Individuals who are judged as unsuitable for the study by the investigator for the other reasons
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Satoshi Suzuki
Organization Shinagawa season terrace health care Clinic
Division name doctor
Zip code
Address 1-2-70 Konan, Minato-ku, Tokyo
TEL 03-3452-3381
Email satoru_suzuki@sempos.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name Fumio Namba
Organization FUJICCO Co., Ltd.
Division name R&D division
Zip code
Address 6-13-4 Minatojimanakamachi, Chuo-ku Kobe, Hyogo
TEL 078-303-5385
Homepage URL
Email f-nanba@fujicco.co.jp

Sponsor
Institute KSO Corporation
Institute
Department

Funding Source
Organization FUJICCO Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 品川シーズンテラス健診クリニック(東京都)

Other administrative information
Date of disclosure of the study information
2016 Year 09 Month 16 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications http://www.lifescience.co.jp/yk/yk17/jun/ab11.html
Number of participants that the trial has enrolled
Results
The continuous ingestion of L. lactis subsp. cremoris FC caused changes in intestinal microflora, improving defecation status and fecal characteristics in healthy subjects prone to constipation.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 08 Month 24 Day
Date of IRB
Anticipated trial start date
2016 Year 09 Month 21 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Effect of Supplement containing Lactococcus lactis subsp. cremoris FC on Defecation in Healthy Humans
-A Randomized, Placebo-controlled, Double-blind Crossover Trial-

FUJICCO Co., Ltd.
T. Toda et al.

Jpn Pharmacol Ther 2017 45(6) 989-997

Management information
Registered date
2016 Year 09 Month 12 Day
Last modified on
2018 Year 05 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027457

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.